This 2021 study evaluated the efficacy of bipolar androgen therapy (BAT) as a first-line treatment for castration-resistant prostate cancer (CRPC). In Cohort C of the RESTORE trial, 29 patients received 400 mg of testosterone cypionate every 28 days alongside luteinizing hormone-releasing hormone agonists or antagonists. The primary endpoint, PSA50 response
